NCT02471196View on ClinicalTrials.gov

Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

308

Participants

Timeline

Start Date

August 14, 2015

Primary Completion Date

October 9, 2017

Study Completion Date

December 4, 2017

Conditions

Alzheimer's Disease

Interventions

DRUG

ORM-12741

ORM-12741 low dose twice a day

DRUG

ORM-12741

ORM-12741 high dose twice a day

DRUG

Placebo

Placebo twice a day

Trial Locations (1)

Unknown

Clinical Research Services Turku - CRST Oy, Turku

Sponsors

Collaborators (1)

Janssen Pharmaceuticals

All Listed Sponsors

collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Orion Corporation, Orion Pharma

INDUSTRY